Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | PPARD | Q03181 | 4/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22386751 | 0.91 | P2RX4 (0.48) | PDE4BPDE4DPDE4APDE4CFFAR1 | |
| SCHEMBL18374460 | 0.89 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CPARP15 | |
| SCHEMBL20463367 | 0.85 | SLC6A9 (0.53) | PDE4BPDE4DPDE4APDE4CFFAR1 | |
| SCHEMBL22386744 | 0.84 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL15968784 | 0.83 | LMNA (0.55) | PDE4BPDE4DPDE4APDE4CFFAR1 | |
| SCHEMBL1861841 | 0.82 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4CSLC6A9 | |
| SCHEMBL15968595 | 0.82 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CFFAR1 | |
| SCHEMBL22837047 | 0.81 | THRA (0.43) | PDE4D | |
| SCHEMBL10148081 | 0.78 | MAP4K4 (0.54) | PDE4BPDE4DPDE4APDE4CPARP15 | |
| SCHEMBL22386752 | 0.78 | HTT (0.48) | PDE4DFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | SUMO2, SUMO1, SUMO3 | PDE4B 3258/4885PDE4D 3714/4885PDE4A 3416/4885 |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | SUMO2, SUMO1, SUMO3 | PDE4B 3258/4885PDE4D 3714/4885PDE4A 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.